You are here:

atazanavir (Reyataz)


Following a full submission

atazanavir (Reyataz) is accepted for use within NHS Scotland in antiretroviral treatment naïve HIV-1 infected adults in combination with other antiretroviral medicinal products.

The combination of atazanavir and ritonavir was non-inferior to a standard boosted protease inhibitor regimen in treatment naïve HIV patients. The combined regimen was associated with lower incidences of diarrhoea and lipid adverse-effects and a higher incidence of hyperbilirubinaemia in this patient population.

Drug Details

Drug Name: atazanavir (Reyataz)
SMC Drug ID: 520/08
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: HIV-1 infected adults
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 December 2008